Clinical Trial Update: Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update assessing the combination of durvalumab with trastuzumab and pertuzumab in HER2-enriched breast cancer, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Pertuzumab (pertuzumab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: The Methodist Hospital Research Institute | Conditions: Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-04-20